03 SEP 2010 05:51                      GI ACCRUAL REPORT - OPEN and recently closed STUDIES                                       
                                                                                                                                  
                                                                                       REGS. REGS. REGS. REGS. REGS.              
                                       R                                                LAST  LAST  LAST  LAST  LAST  # of  # of  
                                       E                                   ACCR. TOTAL    12     6     3    30     7  ACT.  CURR  
STUDY                                  G ARM                                GOAL REGS. Month Month Month  DAYS  DAYS INSTs  IRBs  
-------------------------------------- - --------------------------------- ----- ----- ----- ----- ----- ----- ----- ----- -----  
S0518-Carcinoid,Adv,Octreo/Alpha/Bev   1 1  Octreotide, Bevacizumab          283   122    44    19     7     3     2   150    64  
                                         2  Octreotide,Interferon Alpha-2b         125    47    24     7     3     1              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                   247    91    43    14     6     3              
                                                                                                                                  
                                       *                                   ***** -----                               ***** *****  
                                       s                                           247                                            
                                       2 3  Octreotide, Bevacizumab          283    51    10     7     4     2     1   150    64  
                                         4  Octreotide,Interferon Alpha-2b          29    11     7     3     0     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    80    21    14     7     2     1              
                                                                                                                                  
                                       *                                   ***** -----                               ***** *****  
                                       s                                            80                                            
                                                                                                                                  
S0600-COLREC,MET,CHEMO+CETUX OR BEV    1 1  Cetuximab                        671    16     0     0     0     0     0   234   101  
                                         2  Cetuximab + Lower Bevacizumab           18     0     0     0     0     0              
                                         3  Cetuximab + Higher Bevacizumab          17     0     0     0     0     0              
                                         4  TRNO A: Chemo + Cetuximab                9     9     6     3     0     0              
                                         5  TRNO B: Chemo + Bevacizumab              9     9     6     3     1     0              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    69    18    12     6     1     0              
                                                                                                                                  
                                       *                                   ***** -----                               ***** *****  
                                       s                                            69                                            
                                                                                                                                  
S0713-Rect,Stg2-3,Ox/Cape/Cet+RT->SRG  1 1  Oxal/Cape/Cetux + RT->Surgery     88    13    11     8     3     0     0    92    29  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    13    11     8     3     0     0              
                                                                                                                                  
                                       *                                   ***** -----                               ***** *****  
                                       s                                            13                                            
                                                                                                                                  
S0727-Panc,Met,Gem/Erlotinib/IMC-A12   1 1  Erlotinib+GEM+6 mg/kg IMC-A12    118    10     0     0     0     0     0   165    73  
                                         4  Erlotinib + GEM + IMC-A12               60    55    31    16     8     3              
                                         5  Erlotinib + Gemcitabine                 64    61    33    16     7     2              
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                   134   116    64    32    15     5              
                                                                                                                                  
                                       *                                   ***** -----                               ***** *****  
                                       s                                           134                                            
                                                                                                                                  
S0809-EHCC,Adj,Cape+Gem==>Cape+RT      1 1  Cape+Gem=>Cape+RT                 88    32    26    22    10     4     1   163    70  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    32    26    22    10     4     1              
                                                                                                                                  
                                       *                                   ***** -----                               ***** *****  
                                       s                                            32                                            
                                                                                                                                  
S0941-GallChol,Adv,Sorafenib/Erlotinib 1 1  Sorafenib, Erlotinib              55     3     3     3     3     1     0   111    39  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                     3     3     3     3     1     0              
                                                                                                                                  
                                       *                                   ***** -----                               ***** *****  
                                       s                                             3                                            
                                                                                                                                  
C80405-GI,Met,FOLFOX/FIRI,Bev,Cetux    1 Total Registrations                2289   527    62    33    16     3     0   337   181  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                   527    62    33    16     3     0              
                                                                                                                                  
                                       *                                   ***** -----                               ***** *****  
                                       s                                           527                                            
                                                                                                                                  
E5202-Colon,Stg2,5FU/Leuc/Oxal +/- Bev 1 Total Registrations                       356    68    39    18     6     0         159  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                   356    68    39    18     6     0              
                                                                                                                                  
                                       *                                   ***** -----                               ***** *****  
                                       s                                           356                                            
                                                                                                                                  
R04-Rectum, Capecitabine vs 5FU        1 Total Registrations                        49    11     4     1     0     0   263   125  
                                                                                 ----- ----- ----- ----- ----- -----              
                                                                                    49    11     4     1     0     0              
                                                                                                                                  
                                       *                                   ***** -----                               ***** *****  
                                       s                                            49                                            
                                                                                                                                  














                                                                 

18 rows selected.

03 SEP 2010 05:51                              GI Open Studies with No Registrations                                              
                                                                                                                                  
Study                                    Registration/Phase                  Open Date                                            
---------------------------------------- ----------------------------------- ---------                                            
C80702 Adj FOLFOX+Celecoxib or Placebo   1 Endorsed Study                    22-Jun-10                                            
E1208 Chemo Soraf. in Unresect HCC       1 Endorsed Study                    09-Nov-09                                            
R0848 Panc, Adj, Erlotinib v ChemoRT     1 Endorsed Study                    08-Dec-09                                            
















                                                                 

3 rows selected.

03 SEP 2010 05:51                           GI Recently Closed Studies Accrual Report                                             
                                                                                                                                  
O                                                                                                                                 
P                                                            REGS.  REGS.                                                         
E DATE                                               TOTAL    LAST   LAST                                                         
N CLOSED     REG. ARM                                REGS. 30 DAYS 7 DAYS                                                         
- ---------- ---- --------------------------------- ------ ------- ------                                                         
N 01-Sep-10  1    1  Erlotinib+GEM+6 mg/kg IMC-A12      10       0      0                                                         
                  4  Erlotinib + GEM + IMC-A12          60       8      3                                                         
                  5  Erlotinib + Gemcitabine            64       7      2                                                         
                                                    ------ ------- ------                                                         
                                                       134      15      5                                                         
                                                                                                                                  
                                                                                                                                  









                                                                 

3 rows selected.

03 SEP 2010 05:51                                                                                                        page         1
GI SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES                                                                           
                                                                                                                                       
                                       R                                                                                               
                                       E                                                                       TOTAL                   
STUDY                                  G ARM                               SEGMENT                             REGS.                   
-------------------------------------- - --------------------------------- ----------------------------------- -----                   
S0600-COLREC,MET,CHEMO+CETUX OR BEV    1 1  Cetuximab                       01: Cycle                             16                   
                                         1  Cetuximab                       02: Cycle                             14                   
                                         1  Cetuximab                       03: Cycle                             11                   
                                         1  Cetuximab                       04: Cycle                             10                   
                                         1  Cetuximab                       05: Cycle                              9                   
                                         1  Cetuximab                       06: Cycle                              7                   
                                         1  Cetuximab                       07: Cycle                              4                   
                                         1  Cetuximab                       08: Cycle                              3                   
                                         1  Cetuximab                       09: Cycle                              2                   
                                         1  Cetuximab                       10: Cycle                              2                   
                                         1  Cetuximab                       11: Cycle                              2                   
                                         1  Cetuximab                       12: Cycle                              2                   
                                         1  Cetuximab                       13: Cycle                              2                   
                                         1  Cetuximab                       14: Cycle                              2                   
                                         1  Cetuximab                       15: Cycle                              2                   
                                         1  Cetuximab                       16: Cycle                              2                   
                                         1  Cetuximab                       17: Cycle                              2                   
                                         1  Cetuximab                       18: Cycle                              1                   
                                         2  Cetuximab + Lower Bevacizumab   01: Cycle                             18                   
                                         2  Cetuximab + Lower Bevacizumab   02: Cycle                             17                   
                                         2  Cetuximab + Lower Bevacizumab   03: Cycle                             13                   
                                         2  Cetuximab + Lower Bevacizumab   04: Cycle                             13                   
                                         2  Cetuximab + Lower Bevacizumab   05: Cycle                             12                   
                                         2  Cetuximab + Lower Bevacizumab   06: Cycle                              9                   
                                         2  Cetuximab + Lower Bevacizumab   07: Cycle                              7                   
                                         2  Cetuximab + Lower Bevacizumab   08: Cycle                              5                   
                                         2  Cetuximab + Lower Bevacizumab   09: Cycle                              5                   
                                         2  Cetuximab + Lower Bevacizumab   10: Cycle                              3                   
                                         2  Cetuximab + Lower Bevacizumab   11: Cycle                              4                   
                                         2  Cetuximab + Lower Bevacizumab   12: Cycle                              4                   
                                         2  Cetuximab + Lower Bevacizumab   13: Cycle                              3                   
                                         2  Cetuximab + Lower Bevacizumab   14: Cycle                              3                   
                                         2  Cetuximab + Lower Bevacizumab   15: Cycle                              3                   
                                         2  Cetuximab + Lower Bevacizumab   16: Cycle                              3                   
                                         2  Cetuximab + Lower Bevacizumab   17: Cycle                              3                   
                                         2  Cetuximab + Lower Bevacizumab   18: Cycle                              3                   
                                         2  Cetuximab + Lower Bevacizumab   19: Cycle                              3                   
                                                                    
03 SEP 2010 05:51                                                                                                        page         2
GI SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES                                                                           
                                                                                                                                       
                                       R                                                                                               
                                       E                                                                       TOTAL                   
STUDY                                  G ARM                               SEGMENT                             REGS.                   
-------------------------------------- - --------------------------------- ----------------------------------- -----                   
S0600-COLREC,MET,CHEMO+CETUX OR BEV    1 2  Cetuximab + Lower Bevacizumab   20: Cycle                              3                   
                                         2  Cetuximab + Lower Bevacizumab   21: Cycle                              2                   
                                         2  Cetuximab + Lower Bevacizumab   22: Cycle                              2                   
                                         2  Cetuximab + Lower Bevacizumab   23: Cycle                              1                   
                                         2  Cetuximab + Lower Bevacizumab   24: Cycle                              1                   
                                         2  Cetuximab + Lower Bevacizumab   25: Cycle                              1                   
                                         2  Cetuximab + Lower Bevacizumab   26: Cycle                              1                   
                                         2  Cetuximab + Lower Bevacizumab   27: Cycle                              1                   
                                         2  Cetuximab + Lower Bevacizumab   28: Cycle                              1                   
                                         2  Cetuximab + Lower Bevacizumab   29: Cycle                              1                   
                                         2  Cetuximab + Lower Bevacizumab   30: Cycle                              1                   
                                         2  Cetuximab + Lower Bevacizumab   31: Cycle                              1                   
                                         2  Cetuximab + Lower Bevacizumab   32: Cycle                              1                   
                                         3  Cetuximab + Higher Bevacizumab  01: Cycle                             17                   
                                         3  Cetuximab + Higher Bevacizumab  02: Cycle                             16                   
                                         3  Cetuximab + Higher Bevacizumab  03: Cycle                             16                   
                                         3  Cetuximab + Higher Bevacizumab  04: Cycle                             12                   
                                         3  Cetuximab + Higher Bevacizumab  05: Cycle                             11                   
                                         3  Cetuximab + Higher Bevacizumab  06: Cycle                              9                   
                                         3  Cetuximab + Higher Bevacizumab  07: Cycle                              8                   
                                         3  Cetuximab + Higher Bevacizumab  08: Cycle                              7                   
                                         3  Cetuximab + Higher Bevacizumab  09: Cycle                              6                   
                                         3  Cetuximab + Higher Bevacizumab  10: Cycle                              5                   
                                         3  Cetuximab + Higher Bevacizumab  11: Cycle                              5                   
                                         3  Cetuximab + Higher Bevacizumab  12: Cycle                              5                   
                                         3  Cetuximab + Higher Bevacizumab  13: Cycle                              4                   
                                         3  Cetuximab + Higher Bevacizumab  14: Cycle                              3                   
                                         3  Cetuximab + Higher Bevacizumab  15: Cycle                              3                   
                                         3  Cetuximab + Higher Bevacizumab  16: Cycle                              3                   
                                         3  Cetuximab + Higher Bevacizumab  17: Cycle                              3                   
                                         3  Cetuximab + Higher Bevacizumab  18: Cycle                              3                   
                                         3  Cetuximab + Higher Bevacizumab  19: Cycle                              2                   
                                         3  Cetuximab + Higher Bevacizumab  20: Cycle                              2                   
                                         3  Cetuximab + Higher Bevacizumab  21: Cycle                              2                   
                                         3  Cetuximab + Higher Bevacizumab  22: Cycle                              1                   
                                         3  Cetuximab + Higher Bevacizumab  23: Cycle                              1                   
                                         3  Cetuximab + Higher Bevacizumab  24: Cycle                              1                   
                                                                    
03 SEP 2010 05:51                                                                                                        page         3
GI SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES                                                                           
                                                                                                                                       
                                       R                                                                                               
                                       E                                                                       TOTAL                   
STUDY                                  G ARM                               SEGMENT                             REGS.                   
-------------------------------------- - --------------------------------- ----------------------------------- -----                   
S0600-COLREC,MET,CHEMO+CETUX OR BEV    1 3  Cetuximab + Higher Bevacizumab  25: Cycle                              1                   
                                         3  Cetuximab + Higher Bevacizumab  26: Cycle                              1                   
                                         3  Cetuximab + Higher Bevacizumab  27: Cycle                              1                   
                                         3  Cetuximab + Higher Bevacizumab  28: Cycle                              1                   
                                         4  TRNO A: Chemo + Cetuximab       01: Cycle                              9                   
                                         4  TRNO A: Chemo + Cetuximab       02: Cycle                              4                   
                                         4  TRNO A: Chemo + Cetuximab       03: Cycle                              3                   
                                         4  TRNO A: Chemo + Cetuximab       04: Cycle                              1                   
                                         4  TRNO A: Chemo + Cetuximab       05: Cycle                              1                   
                                         4  TRNO A: Chemo + Cetuximab       06: Cycle                              1                   
                                         4  TRNO A: Chemo + Cetuximab       07: Cycle                              1                   
                                         4  TRNO A: Chemo + Cetuximab       08: Cycle                              1                   
                                         4  TRNO A: Chemo + Cetuximab       09: Cycle                              1                   
                                         4  TRNO A: Chemo + Cetuximab       10: Cycle                              1                   
                                         4  TRNO A: Chemo + Cetuximab       11: Cycle                              1                   
                                         4  TRNO A: Chemo + Cetuximab       12: Cycle                              1                   
                                         4  TRNO A: Chemo + Cetuximab       13: Cycle                              1                   
                                         5  TRNO B: Chemo + Bevacizumab     01: Cycle                              9                   
                                         5  TRNO B: Chemo + Bevacizumab     02: Cycle                              5                   
                                         5  TRNO B: Chemo + Bevacizumab     03: Cycle                              5                   
                                         5  TRNO B: Chemo + Bevacizumab     04: Cycle                              4                   
                                         5  TRNO B: Chemo + Bevacizumab     05: Cycle                              3                   
                                         5  TRNO B: Chemo + Bevacizumab     06: Cycle                              1                   
                                         5  TRNO B: Chemo + Bevacizumab     07: Cycle                              1                   
                                         5  TRNO B: Chemo + Bevacizumab     08: Cycle                              1                   
                                         5  TRNO B: Chemo + Bevacizumab     09: Cycle                              1                   
                                         5  TRNO B: Chemo + Bevacizumab     10: Cycle                              1                   
                                         5  TRNO B: Chemo + Bevacizumab     11: Cycle                              1                   
                                         5  TRNO B: Chemo + Bevacizumab     12: Cycle                              1                   
                                         5  TRNO B: Chemo + Bevacizumab     13: Cycle                              1                   
                                         5  TRNO B: Chemo + Bevacizumab     14: Cycle                              1                   
                                                                                                                                       
                                                                                                                                       
S0713-Rect,Stg2-3,Ox/Cape/Cet+RT->SRG  1 1  Oxal/Cape/Cetux + RT->Surgery   01: Chemotherapy                      13                   
                                         1  Oxal/Cape/Cetux + RT->Surgery   02: Chemotherapy plus Radiation        3                   
                                                                                                                                       
                                                                                                                                       
                                                                    
03 SEP 2010 05:51                                                                                                        page         4
GI SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES                                                                           
                                                                                                                                       
                                       R                                                                                               
                                       E                                                                       TOTAL                   
STUDY                                  G ARM                               SEGMENT                             REGS.                   
-------------------------------------- - --------------------------------- ----------------------------------- -----                   
S0727-Panc,Met,Gem/Erlotinib/IMC-A12   1 1  Erlotinib+GEM+6 mg/kg IMC-A12   01: 1 treatment cycle                 10                   
                                         1  Erlotinib+GEM+6 mg/kg IMC-A12   02: 1 treatment cycle                  8                   
                                         1  Erlotinib+GEM+6 mg/kg IMC-A12   03: 1 treatment cycle                  2                   
                                         1  Erlotinib+GEM+6 mg/kg IMC-A12   04: 1 treatment cycle                  1                   
                                         4  Erlotinib + GEM + IMC-A12       01: 1 treatment cycle                 60                   
                                         4  Erlotinib + GEM + IMC-A12       02: 1 treatment cycle                 35                   
                                         4  Erlotinib + GEM + IMC-A12       03: 1 treatment cycle                 21                   
                                         4  Erlotinib + GEM + IMC-A12       04: 1 treatment cycle                 15                   
                                         4  Erlotinib + GEM + IMC-A12       05: 1 treatment cycle                 10                   
                                         4  Erlotinib + GEM + IMC-A12       06: 1 treatment cycle                  6                   
                                         4  Erlotinib + GEM + IMC-A12       07: 1 treatment cycle                  2                   
                                         4  Erlotinib + GEM + IMC-A12       08: 1 treatment cycle                  1                   
                                         4  Erlotinib + GEM + IMC-A12       09: 1 treatment cycle                  1                   
                                         5  Erlotinib + Gemcitabine         01: 1 treatment cycle                 64                   
                                         5  Erlotinib + Gemcitabine         02: 1 treatment cycle                 42                   
                                         5  Erlotinib + Gemcitabine         03: 1 treatment cycle                 23                   
                                         5  Erlotinib + Gemcitabine         04: 1 treatment cycle                 13                   
                                         5  Erlotinib + Gemcitabine         05: 1 treatment cycle                  8                   
                                         5  Erlotinib + Gemcitabine         06: 1 treatment cycle                  6                   
                                         5  Erlotinib + Gemcitabine         07: 1 treatment cycle                  4                   
                                         5  Erlotinib + Gemcitabine         08: 1 treatment cycle                  1                   
                                         5  Erlotinib + Gemcitabine         09: 1 treatment cycle                  1                   
                                         5  Erlotinib + Gemcitabine         10: 1 treatment cycle                  1                   
                                                                                                                                       
                                                                                                                                       
S0809-EHCC,Adj,Cape+Gem==>Cape+RT      1 1  Cape+Gem=>Cape+RT               01: Adj. Chemo Cycle 1                32                   
                                         1  Cape+Gem=>Cape+RT               02: Adj. Chemo Cycle 2                21                   
                                         1  Cape+Gem=>Cape+RT               03: Adj. Chemo Cycle 3                15                   
                                         1  Cape+Gem=>Cape+RT               04: Adj. Chemo Cycle 4                11                   
                                         1  Cape+Gem=>Cape+RT               05: Chemoradiotherapy                  6                   
                                                                                                                                       
                                                                                                                                       
S0941-GallChol,Adv,Sorafenib/Erlotinib 1 1  Sorafenib, Erlotinib            01: CYCLE                              3                   
                                                                                                                                       
                                                                                                                                       


                                                                    

136 rows selected.

SWOG StatCtr Home Page 1 row selected.